2/3
03:55 pm
alt
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
Neutral
Report
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
2/2
10:02 am
alt
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
Low
Report
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
1/29
05:54 pm
alt
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Medium
Report
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
1/29
01:31 pm
alt
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Low
Report
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
1/29
07:41 am
alt
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
09:25 pm
alt
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
High
Report
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
1/27
06:00 pm
alt
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
High
Report
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/5
07:54 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
Low
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
1/5
07:30 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Medium
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
12/19
07:02 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial [Yahoo! Finance]
12/19
06:30 am
alt
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
High
Report
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
12/1
07:44 am
alt
Altimmune announces CEO transition [Seeking Alpha]
Medium
Report
Altimmune announces CEO transition [Seeking Alpha]
12/1
07:30 am
alt
Altimmune Announces CEO Transition and Succession Plan
Medium
Report
Altimmune Announces CEO Transition and Succession Plan
11/26
07:53 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/26
07:30 am
alt
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
08:46 am
alt
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Altimmune (NASDAQ:ALT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/11
09:21 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 [Yahoo! Finance]
11/11
08:51 am
alt
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
Low
Report
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025